Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease

Objective To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD). Methods Using a randomized, double‐blind, placebo‐controlled design, nine patients received placebo and...

Full description

Saved in:
Bibliographic Details
Published in:International journal of geriatric psychiatry 2004-01, Vol.19 (1), p.1-8
Main Authors: Leroi, Iracema, Brandt, Jason, Reich, Stephen G., Lyketsos, Constantine G., Grill, Stephen, Thompson, Richard, Marsh, Laura
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biological and medical sciences
cholinesterase inhibitors
Cholinesterase Inhibitors - adverse effects
Cholinesterase Inhibitors - therapeutic use
cognitive impairment
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
dementia
Dementia - drug therapy
Dementia - etiology
donepezil
Double-Blind Method
Female
Geriatrics
Humans
Indans - adverse effects
Indans - therapeutic use
Male
Medical sciences
Memory Disorders - drug therapy
Memory Disorders - etiology
Middle Aged
Neurology
neuropsychiatry
Neuropsychological Tests
Nootropic Agents - adverse effects
Nootropic Agents - therapeutic use
Parkinson Disease - psychology
Parkinson' s disease
Pilot Projects
Piperidines - adverse effects
Piperidines - therapeutic use
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD). Methods Using a randomized, double‐blind, placebo‐controlled design, nine patients received placebo and seven patients received donepezil (2.5–10 mg/day) for a mean (SD) duration of 15.2 (3.4) weeks. The primary efficacy outcomes were derived from a neuropsychological battery that assessed global cognitive status as well as memory, attention, psychomotor speed, and visuospatial and executive functions. Secondary efficacy outcomes were psychiatric symptom and activities of daily living ratings. Primary safety measures were motor signs and assessments of adverse effects. Results Patients on donepezil showed selective and significant (p
ISSN:0885-6230
1099-1166
DOI:10.1002/gps.993